Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | EP300 | Q09472 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4225849 | 0.97 | SMN1; SMN2 (0.33) | ALOX15NPSR1ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL27683933 | 0.97 | SMN1; SMN2 (0.33) | ALOX15NPSR1ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL27683921 | 0.97 | SMN1; SMN2 (0.33) | ALOX15NPSR1ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL27664279 | 0.95 | — | — | |
| SCHEMBL6092390 | 0.89 | — | — | |
| SCHEMBL8487791 | 0.78 | KDM4E (0.36) | ALOX15 | |
| SCHEMBL5586069 | 0.78 | SMN1; SMN2 (0.32) | ALOX15SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL28777414 | 0.77 | KDM4E (0.35) | ALOX15 | |
| SCHEMBL27683963 | 0.77 | ALOX15 (0.40) | ALOX15EP300HIF1ACREBBP | |
| SCHEMBL27656025 | 0.77 | SCN1A (0.39) | NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024067477-A1 | ANTI-CD33 ANTIBODY AND ANTI-CD33 ANTIBODY-DRUG CONJUGATE AND USE THEREOF | 成都百利多特生物药业有限责任公司 | 2024-04-04 | — | — | WO | disclosed |
| US-6008398-A | Non-nucleotide phosphorus ester oligomers | GENZYME CORPORATION (US) | 1999-12-28 | — | — | US | disclosed |
| US-5919965-A | Non-nucleotide phosphorus ester oligomers | GENZYME CORPORATION (US) | 1999-07-06 | — | — | US | disclosed |
| EP-0880532-A4 | NON-NUCLEOTIDE PHOSPHOROUS ESTER OLIGOMERS | PHARMAGENICS INC (US) | 1999-06-09 | — | — | EP | disclosed |
| EP-0880532-A1 | NON-NUCLEOTIDE PHOSPHOROUS ESTER OLIGOMERS | PHARMAGENICS, INC. (US) | 1998-12-02 | — | — | EP | disclosed |
| EP-0804443-A4 | NON-NUCLEOTIDE PHOSPHORUS ESTER OLIGOMERS | PHARMAGENICS INC (US) | 1998-04-29 | — | — | EP | disclosed |
| EP-0804443-A1 | NON-NUCLEOTIDE PHOSPHORUS ESTER OLIGOMERS | PHARMAGENICS, INC. (US) | 1997-11-05 | — | — | EP | disclosed |
| WO-1997028168-A1 | NON-NUCLEOTIDE PHOSPHOROUS ESTER OLIGOMERS | PHARMAGENICS, INC. (US) | 1997-08-07 | — | — | WO | disclosed |
| WO-1996022297-A9 | NON-NUCLEOTIDE PHOSPHORUS ESTER OLIGOMERS | — | 1996-10-03 | — | — | WO | disclosed |
| WO-1996022297-A1 | NON-NUCLEOTIDE PHOSPHORUS ESTER OLIGOMERS | PHARMAGENICS, INC. (US) | 1996-07-25 | — | — | WO | disclosed |